ReCode Therapeutics™ ("ReCode") ("the
Company"), a private biopharmaceutical company pioneering precision medicines for pulmonary
diseases, today announced the close of an oversubscribed $80 million Series A financing round.
OrbiMed Advisors LLC and Colt Ventures co-led the round, with participation from MPM Capital, Vida
Ventures LLC, Hunt Technology Ventures, L.P. and Osage University Partners. ReCode will use the
proceeds to continue the preclinical development of its lead programs in primary ciliary dyskinesia
("PCD") and cystic fibrosis ("CF"). The Company expects to file an Investigational New Drug
Application ("IND") for both programs in 2021. In addition, the Company will advance its proprietary
non-viral lipid nanoparticle ("LNP") delivery platform for organ-specific delivery of RNA therapies and
gene editing components.
"Our preclinical studies demonstrate that our targeted RNA therapies have great potential for the
treatment of life-threatening pulmonary diseases," commented David Lockhart, Ph.D., CEO and
president, ReCode Therapeutics. "We are pleased to close this financing round with world-class
investors who believe in the bold vision of our new company. With these additional resources, we're
focused on advancing our preclinical programs into the clinic over the next two years."
Lockhart continued, "I'm especially grateful to ReCode's founders, professors Daniel Siegwart, Ph.D.,
and Philip Thomas, Ph.D., at the University of Texas Southwestern Medical Center, and Professor
Emeritus Arthur Johnson from Texas A&M University whose foundational research played an
instrumental role in cultivating both the LNP delivery platform and the CF therapeutic program. Finally,
we are grateful to the Cystic Fibrosis Foundation, whose financial support has allowed us to play a
pivotal role in understanding the pathogenesis of CF and led to the development of a novel therapeutic
approach for correcting nonsense mutations for this severe disease."
Along with the financing, ReCode has appointed a new board of directors. The directors comprise
representatives from the Company including Dr. David Lockhart and key investors including Dr. Peter
Thompson, partner at OrbiMed, Ed Hurwitz, J.D., managing director at MPM Capital, Helen S. Kim,
managing director at Vida Ventures, R.A. Session II, chief business officer of the gene therapy
subsidiaries at BridgeBio, and ReCode founder and new vice president of R&D, Dr. Michael Torres.
"We believe that ReCode has an exceptional opportunity to advance its targeted RNA therapies and
LNP delivery platform to address the critical needs of patients living with devastating genetic respiratory
diseases," said Dr. Peter Thompson, partner, OrbiMed. "The board looks forward to supporting
ReCode's evolution as it moves these compelling therapies into the clinic."
Chardan acted as sole placement agent on the Series A financing, and as M&A advisor to ReCode
Therapeutics.
About ReCode Therapeutics
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for genetic
respiratory diseases with significant unmet medical need. ReCode's diverse pipeline includes lead
programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The Company's
proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and
precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery.
ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities,
including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for
diseases caused by nonsense mutations, and gene editing. For more information, visit
www.recoderx.com
About OrbiMed Advisors LLC
OrbiMed is a leading healthcare investment firm, with over $14 billion in assets under management.
OrbiMed invests globally across the healthcare industry, from start-ups to large multinational
corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds.
OrbiMed maintains offices in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and
Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and
global team resources and support to help build world-class healthcare companies. To learn more, visit
www.orbimed.com.
About Colt Ventures
Colt Ventures is a family office that was established in 2003 to invest the capital of Darren Blanton.
Colt invests in a variety of private and public companies, and has deep domain expertise in
biotechnology and energy. Dr. Sundeep Agrawal leads the firm's investment activities with a focus on
biotechnology/therapeutics. Colt is headquartered in Dallas with a presence in New York City. To learn
more, visit www.coltventures.com.